Combinations with proteasome inhibitors are currently being investigated to improve the therapy of hematological malignancies. We previously found that proteasome inhibition by bortezomib failed to sensitize anti-CD30 antibody (Ab)-based lymphoma cell killing. In this study, we demonstrate in L540 Hodgkin's lymphoma cells that proteasome inhibition not only communicates apoptosis but also more rapidly causes a loss of CD30 antigen from cell membrane and a simultaneous release of soluble CD30, a targeting competitor. This shedding was catalyzed by the tumor necrosis factor (TNF)-a-converting enzyme (TACE, ADAM17) and blocked by the ADAM17-selective inhibitor, Ro32-7315. In parallel with CD30 shedding, bortezomib caused the generation of reactive oxygen species (ROS). As apoptosis and shedding were inhibited by the radical scavenger, N-acetyl-L-cysteine, ROS might have a pivotal function in both effects. In contrast, the pan-caspase inhibitor, zVAD-fmk, blocked bortezomib-induced apoptosis but not CD30 shedding, and Ro32-7315 blocked shedding but allowed apoptosis. This suggests independent terminal signaling pathways that are conflicting in Ab-based immunotherapy. Consequently, shedding inhibition substantially improved the synergistic antitumor efficacy of the human anti-CD30 Ab, MDX-060, and bortezomib. As proteasome inhibition also stimulated loss of TNF receptors, interleukin-6 receptor and syndecan-1 in different leukemia and lymphoma cell lines, we concluded that proteasome inhibition might impede targeted therapy against antigens susceptible to shedding.
Introduction
CD30 is selectively overexpressed in the malignant cell population of Hodgkin's lymphoma (HL). Despite this selectivity, the clinical benefit of anti-CD30 immunotherapy in HL patients is poor. 1, 2 This is at least in part due to CD30 shedding that leads to the generation of a soluble serum competitor. 3, 4 In addition, aberrant transcription factor nuclear factor-kB survival activity, governed by the overexpression of nuclear factor-kB-inducing kinase, is a hallmark of HL and participates in apoptosis resistance of tumor cell lines. 5, 6 The proteasome inhibitor, bortezomib, inhibits the nuclear factor-kB signaling pathway by blocking the degradation of inhibitors of nuclear factor-kB (I-kB species). 7 We previously tested the combination of bortezomib and the fully human anti-CD30 antibody (Ab), MDX-060, in the anti-CD30 Ab-responsive HL cell line L540, both in vitro and in a SCID mouse model. 8 Although preincubation with MDX-060 enhanced the cytotoxic potency of bortezomib, simultaneous or preincubation with bortezomib failed to improve Ab therapy. Currently, there is no explanation for this defect. The reports on endothelial and epithelial cells have shown that proteasome inhibition can lead to a metalloproteinase-dependent loss of cell surface tumor necrosis factor (TNF) receptor I/II (CD120a/b). 9, 10 Both, CD120a and CD30 are released by TNF-a-converting enzyme (TACE, ADAM17). 4, 11 We therefore tested whether bortezomib impairs Ab-based CD30 targeting by reducing the antigen density. In this study, we show that bortezomib stimulates ADAM17-dependent shedding of CD30 in L540 HL cells involving reactive oxygen species (ROS). ADAM17 inhibition blocked this CD30 loss and improved the synergism of MDX-060 and bortezomib.
Materials and methods

Cells and reagents
We used the CD30-positive HL cell lines L540 and L428, the large cell anaplastic lymphoma cell line Karpas299, as well as the CD30-negative acute lymphoblastic leukemia cell line Reh, Jurkat (T-acute lymphoblastic leukemia) and RPMI 8226 (multiple myeloma). Cells were cultivated at 37 1C and 5% CO 2 in RPMI-1640 containing 10% heat-inactivated fetal calf serum, penicillin (50 mg/ml) and streptomycin (50 mg/ml). The ADAM17 ( À/À ) mouse embryonal fibroblast cells were received from Dr R Black (Amgen Incorporated, Seattle, WA, USA) and the ADAM10 ( À/À ) cells were from Dr D Hartmann (Center for Human Genetics, Leuven, Belgium). They were cultivated in Dulbecco's modified Eagle's medium/5% fetal calf serum. The anti-CD30 monoclonal Abs, Ki-1, Ki-2, Ki-3 and Ki-4, were used for the detection of CD30 and soluble CD30 (sCD30).
Transfection
In 24-well plates, aliquots of 1 Â 10 5 cells were cultivated overnight. Medium was removed from adherent cells and 400 ml Opti-MEM I (Invitrogen, Karlsruhe, Germany) was added. DNA (0.8 mg DNA/50 ml Opti-MEM I) and LipofectAmin (Invitrogen; 2/48 ml Opti-MEM I) were prepared separately and incubated for 5 min. Then, DNA and LipofectAmin solutions were mixed and incubated for 30 min before being added to the cells. Cells were incubated for 36 h before use.
Western blot
Whole cell lysates generated after 2 min boiling with SDS sample buffer and cell-free supernatants were developed in SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Filters were blocked with phosphate-buffered saline containing 1% fat-free dry milk and then incubated at 4 1C with anti-CD30 and anti-b-actin Abs as indicated. Finally, they were stained with peroxidase-coupled goat anti-mouse immunoglobulin-G and ECL reagent (GE Healthcare, Freiburg, Germany).
Reactive oxygen species detection
Cells were incubated with or without bortezomib ±100 mM N-acetyl-L-cysteine (NAC; Sigma-Aldrich, Taufkirchen, Germany) as indicated. For the final 15 min of incubation, 2 0 ,7 0 -dichlorodihydro-fluorescein diacetate (Sigma-Aldrich; 5 mM) was added and incubated at 37 1C. ROS were analyzed using flow cytometry (BD FACSCalibur, Becton Dickinson GmbH, Heidelberg, Germany).
Determination of sCD30
The test was performed as previously described. 14 
XTT viability assay
In 96-well plates, cells (2 Â 10 4 /well) were cultivated in 200 ml of RPMI-1640 medium containing 10% fetal calf serum. The test was started by preincubating cells with anti-CD30 Ab MDX-060 (50 ng/ml) þ GaH-IgG (100 ng/ml). One hour later, increasing concentrations of bortezomib were added. The same was also carried out in reverse order. Ro32-7315 (1.5 mM) was applied to experiments when indicated. Then, cells were incubated for 48 h and pulsed for additional 4 h with 50 ml of fresh serum-free medium containing 1.5 mM XTT (Sigma-Aldrich) and 0.025 mM N-methyl-phenazonium-methyl-sulfate (Sigma-Aldrich). Absorbance of the reaction was determined using m-Quant-ELISA reader (Bio-Tek Instruments, Winooski, VT, USA) at 450 versus 650 nm. The concentration required to achieve a 50% reduction of XTT turnover (IC 50 ) compared with untreated controls was calculated.
Analysis of apoptosis
Cells (2 Â 10 5 /ml) were cultivated in RPMI-1640/10% fetal calf serum with or without agents as indicated. Then, cells were washed once with phosphate-buffered saline and subsequently suspended in annexin binding buffer (10 mM HEPES/NaOH, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4). They were incubated for 10 min on ice with annexin V-phycoerythrin and 7-aminoactinomycin D. Cells without any previous cytotoxic treatment were used to determine background apoptosis. Assays were performed in triplicate and analyzed using flow cytometry and Cellquest software (BD FACSCalibur, Becton Dickinson GmbH).
Results and discussion
Bortezomib stimulates ADAM17-catalyzed shedding of CD30
Bortezomib caused a loss of CD30 from L540 cells. The effect was minute after 7 h but increased after 14 and 20 h of incubation ( Figure 1a ). The portion of dead cells increased under treatment, that is, 1, 8 and 18% after 7, 14 and 20 h, respectively (data not shown). However, the loss was not restricted to dead cells, as 7-amino-actinomycin D-negative cells showed an effect similar to the whole cell population. In all cases, receptor reduction was clearly inhibited by the broadspectrum metalloproteinase inhibitor, marimastat, indicating a function of metalloproteinases. Soluble CD30 was determined in the cell-free supernatants from the same experiment. As shown in Figure 1b , 1.4-fold elevated sCD30 levels (Po0.0001) were already found after 7 h of stimulation. After 14 h, the gain was 2.3-fold (Po0.0001) and after 20 h the gain was 2.9-fold (P ¼ 0.0129). Western blot analysis confirmed the stimulated conversion from 120 kDa CD30 to 90 kDa sCD30 after 14 h of bortezomib treatment ( Figure 1c) . Here, the effects were also inhibited by metalloproteinase inhibition. Despite the enhanced sCD30 release, the CD30 surface expression remained stable after 7 h of stimulation. This might be explained by an activated receptor transport after bortezomib treatment, which compensates the loss in the first hours of stimulation. 9 Because of the invariant receptor density after 7 h and an appreciable cell death after 20 h of bortezomib stimulation, we stimulated for 14 h in subsequent experiments, unless otherwise indicated. Shedding stimulation was dose-dependent and reached plateau values at 10 ng/ml in L540 cells resulting in a 70% reduction of cell surface CD30 and a threefold gain of sCD30 compared with non-treated controls ( Figure 1d ). Stimulation of CD30 shedding was also found in L428 (HL) and Karpas299 (large cell anaplastic lymphoma) cells, as indicated by a reduction of cell surface CD30 and an increased release of sCD30 (P ¼ 0.0372 and 0.0041, respectively) (Figures 1e and f) . This treatment caused a 10 and 8% loss of viability in L428 and Karpas299 cells, respectively. Owing to the lack of malignant Hodgkin's cells in the blood stream of patients, it is very difficult to test primary cells. However, bortezomib was tested in clinical trials with HL patients. No clinical benefit was observed as single agent or in combination with gemcitabine or dexamethasone. [15] [16] [17] The trial combining bortezomib and dexamethasone was prematurely closed after 12 patients due to lack of response. Serum was available from three patients who received treatment according to the protocol until the end of study. In all cases sCD30 levels clearly increased under therapy (3-, 5.3-and 6-fold; data not shown). Despite the low number of cases and although it could not be finally demonstrated that this effect was caused by bortezomib alone, this finding provides some evidence for bortezomibstimulated shedding in vivo.
The metalloproteinases, ADAM10 and ADAM17, have been shown to catalyze CD30 shedding, their individual participation depends on the way of triggering. 4, 18 We tested the role of these candidate enzymes in bortezomib-stimulated CD30 shedding using either ADAM10-deficient (ADAM10 À / À ) or ADAM17-defective (ADAM17 À / À ) murine embryonic fibroblasts. Both showed some constitutive release of sCD30, indicating a certain releasing enzyme redundancy (Figure 2a) . Although 100 ng/ml of bortezomib doubled the sCD30 release (707.5-1569 U/ml, Po0.0001) in ADAM10-defective cells with functional ADAM17, it failed to stimulate CD30 shedding in ADAM17-defective cells. We also applied the ADAM17-selective inhibitor, Ro32-7315 13 ( Figure 2b ). It blocked bortezomib-stimulated sCD30 release from L540 cells with an IC 50 of approximately 230 nM. This concentration is comparable with the IC 50 of the potent broad-spectrum inhibitor, marimastat. As the gelatinase inhibitor (Ro28-2653) and the ADAM10-selective inhibitor (GI254023X) showed only weak inhibition at higher concentrations, we concluded that bortezomib triggers CD30 shedding in a ADAM17-dependent manner (Figures 2b and c) .
We tested the effect of bortezomib on other surface proteins that are both, interesting targets for immunotherapy and subjects of proteolytic cleavage. Among them, syndecan-1 (CD138) and the interleukin-6 (IL-6) receptor (CD126) are expressed on L540 cells (Figure 3 ). CD138 is expressed on B cells and used as target in plasma cell malignancies.
19 CD126 is expressed on hepatocytes, leukocytes and its signaling participates in the pathogenesis of rheumatoid arthritis and some tumors. Targeting CD126 was found to improve the outcome of rheumatoid arthritis. 20 Both antigens were downregulated on bortezomib treatment on L540 HL cells and on Jurkat T-acute lymphoblastic leukemia cells. Here, the loss was also inhibited by ADAM17-selective inhibition. However, downregulation of cell (e and f) Karpas299 and L428 cells were incubated for 14 h with bortezomib (10 ng/ml) in the presence or absence of marimastat (1.5 mM). CD30 expression was determined by flow cytometry from viable cells after forward/side scatter gating and sCD30 was determined by ELISA from three or four independent experiments.
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surface proteins by bortezomib might not represent a general phenomenon. RPMI8226, a multiple myeloma cell line that was successfully killed upon CD138 targeting, showed no detectable loss of CD138 after treatment (data not shown). Thus, it is tempting to speculate that proteasome inhibition not only governs tumor survival by inhibiting nuclear factor-kB signaling but also modifies the expression of surface proteins, a process which might negatively influence immunotherapeutic approaches in certain malignancies.
Mechanism of bortezomib-stimulated shedding induction
To better understand the downstream effects, we compared the kinetics of bortezomib-induced shedding and apoptosis. Significantly elevated sCD30 levels were first detectable after 3 h of incubation (P ¼ 0.0474) (5-20 h; Po0.0001), with a maximum gain between 3 and 7 h (Figure 4) . However, an elevated annexin V staining, indicating increased apoptosis was not observed before 7 h of incubation. This shows that the contribution of bortezomib to receptor release sets in more rapidly than its contribution to cell killing. We therefore speculate that CD30 shedding is not a consequence of apoptosis but occurs earlier or in parallel.
Apoptosis induction by bortezomib in multiple myeloma or mantle cell lymphoma is at least in part communicated by elevated and sustained levels of ROS participating in downstream generation of DNA fragments. 21, 22 Moreover, ROS production may cause ectodomain shedding involving ADAM17 or ADAM10. 23, 24 We tested ROS production in L540 cells in response to bortezomib (Figure 5a ). Comparing stimulated and untreated cells in a kinetic, elevated ROS levels were detectable after 3 h of incubation (relative gain ¼ 1.188±0.048). The gain failed when cells were preincubated with the radical scavenger NAC (relative gain ¼ 1.03 ± 0.01) indicating in a significant generation of NAC-sensitive ROS at this time point (P ¼ 0.0098). ROS levels increased after prolonged incubation periods, resulting in a 1.6-fold versus 1.1-fold (P ¼ 0.0308) elevation after 4 h and a 1.9-fold versus 1.1-fold (Po0.0001) gain after 6 h of incubation. Thus, in kinetic evaluations, the generation of ROS from bortezomib-stimulated L540 cells correlated with elevated sCD30 levels in the cell-free supernatants (Figure 4) .
We tested the function of elevated ROS levels in CD30 shedding from L540 cells and found that bortezomib (10 ng/ml) and H 2 O 2 (1 mM) stimulated sCD30 release (Figure 5b ). In both cases it was inhibited by NAC (1 mM, P ¼ 0.0012) and Ro32-7315 (1.5 mM, Po0.0001), indicating a role of ROS and ADAM17. On the other hand, bortezomib and H 2 O 2 also caused apoptosis as demonstrated by annexin V staining. Bortezomib-and H 2 O 2 -induced apoptosis could be inhibited by NAC, indicating a pivotal function of ROS in shedding as well as in induction of apoptosis.
In neutrophils, apoptotic cell death is the natural stimulus of ADAM17-dependent IL-6 receptor (CD126) shedding. For this shedding event prior activation of caspases 3, 8 and 9 is required. 25 We tested the role of caspases in bortezomibstimulated CD30 shedding using the pan-caspase inhibitor, zVAD-fmk. In contrast to IL-6 receptor release in neutrophils, sCD30 release in L540 cells was not inhibited by pan-caspase inhibition ( Figure 5c ). As zVAD-fmk was able to inhibit bortezomib-induced apoptosis in L540 cells as detected by annexin V staining, we concluded that sCD30 release is not caspase-dependent. In addition, apoptosis induction by CD95(Fas) ligation also caused caspase-independent CD30 shedding in L540 cells (data not shown). Thus, CD30 shedding in L540 cells correlates with different kinds of apoptosis induction but is not dependent on apoptosis itself because caspase activation is no prerequisite for this process. Instead, at least upon bortezomib stimulation, ROS seem to represent a common player in the apoptosis and shedding pathway.
Inhibition of ADAM17 increases the cytotoxicity of bortezomib and MDX-060 against L540
We also tested the role of shedding stimulation on the impact of anti-CD30 immunotherapy. The antitumor efficacy of the human anti-CD30 Ab, MDX-060, in L540 cells is enhanced by anti-human IgG Abs (GaH-IgG). 26 Such crosslinking of CD30 forms visible cell aggregates as indicated in Figure 6a . Aggregate formation depends on antigen density. We observed that bortezomib pretreatment abrogates clot formation that was reverted by concomitant ADAM17 inhibition. As inhibition of ADAM17 suppressed bortezomib-induced CD30 shedding, we speculated that downregulation of cell surface CD30 by bortezomib pretreatment might negatively influence CD30-targeted immunotherapy.
To confirm this speculation, we evaluated the influence of subtoxic concentrations of Ro32-7315 (1.5 mM) and MDX-060 on the cytotoxic potential of increasing concentrations of bortezomib (Figure 6b ). Both L540 and Reh control cells were sensitive to bortezomib in XTT viability assays (IC 50 : 6 and 10 ng/ml, respectively). In agreement with our previous data, the combination of bortezomib and MDX-060 showed synergistic cytotoxicity in L540 cells but not in the control cells lacking CD30. 8 Pretreatment with Ab is essential for synergy which is not seen after bortezomib coapplication or pretreatment. However, inhibition of CD30 shedding by Ro32-7315 suppressed this failure of synergy.
To verify the role of ADAM17-catalyzed shedding in bortezomib-supported immunotargeting of L540 cells, we analyzed the impact of Ro32-7315 by simultaneous staining of late apoptosis with 7-amino-actinomycin D and early apoptosis with annexin V-phycoerythrin in flow cytometry. To minimize a direct impact of bortezomib on apoptosis, we used a subtoxic concentration (4 ng/ml) that was still able to induce CD30 shedding. As demonstrated in Figure 6c , ADAM17 inhibition alone (Ro) had no effect on cell viability but was able to triple the rate of early apoptotic cells (lower right gate) after bortezomib preincubation þ MDX-060 incubation (bo þ MDX and bo þ Ro þ MDX) from 8.34 to 29.01% and more than double the rate of late apoptotic/necrotic cells from 6.38 to The relative production of ROS was determined by comparing the mean fluorescence of treated versus untreated cells at each time point of four independent experiments (NS, not significant). The relative (b þ c) L540 cells were stimulated for 14 h with bortezomib (10 ng/ml) or H 2 O 2 (1 mM) in the presence or absence of NAC (1 mM), Ro32-7315 (Ro; 1.5 mM) or zVAD-fmk (100 mM). Soluble CD30 was determined in the cell-free supernatants by ELISA. Cell viability/apoptosis was evaluated by flow cytometry after 7-amino-actinomycin D and annexin V staining. Dot blot analysis shows the percentage of viable (lower lift) and apoptotic (upper and lower right) cells. 13 .31% (upper right gate). These data confirm that induction of CD30 shedding by bortezomib substantially perturbs anti-CD30-targeted immunotherapy.
Many membrane proteins regulate their density and functionality through metalloproteinase-dependent cleavage of their ectodomains. Some of them, CD30, CD44, CD138 and HER2 for instance, are potential target antigens due to their selective overexpression in certain tumor entities. 27 Another example is CD126. After shedding, the soluble ectodomain is still able to bind IL-6. The resulting soluble receptor-ligand complexes contribute to chronic inflammation by initiating IL-6 signaling in CD26-negative immune cells (transsignaling). 28 Others, such as released ErbB ligands, L1, CD44 and MICA, promote tumor proliferation and migration or worsen immune surveillance after cleavage. 27 ADAM17 participates in most cleavage events and is overexpressed in many tumors suggesting an adverse role of this enzyme in tumor progression and treatment. We showed that the cleavable antigens, CD30, CD138 and CD126, were reduced in their cell membrane density after bortezomib treatment. Using CD30 as an example, we clearly demonstrated that bortezomib impedes immunotherapy targeting CD30 in HL cells. This effect should be carefully considered in therapeutic approaches, particularly when released proteins are involved in the pathomechanism of the malignancy.
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